Business
IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate
Independent study concluded:- IceCure system offers significant advantage in ability to re-treat tumors that are initially resistant, achieving a subsequent
About this update from Icecure Medical Ltd.
[{"type":"text","content":"Independent study concluded:- IceCure system offers significant advantage in ability to re-treat tumors that are initially resistant, achieving a subsequent local control rate of 100%- 92.4% of patients (N= 24) were discharged the day after cyroablation- The technology's ability to preserve renal function post-treatment is paramount for patients' quality of life- Findings serve as a guide for medical professionals in choosing efficient, cost-effective, and patient-friendly treatment options, thereby benefiting society at large by optimizing kidney tumor managementSuccess across multiple indications supports ProSense®'s commercialization, particularly in facilities that can use one device across multiple specialtiesCAESAREA, Israel, Nov. 28, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the latest release of a study (the \"Study\") in a series of independent studies of ProSense® published in peer-reviewed journals demonstrating safety and efficacy. The Study, titled \"Single-Probe Percutaneous Cryoablation with Liquid Nitrogen for the Treatment of T1a Renal Tumors\", published in Cancers, demonstrated the safety and efficacy of ProSense® in treating malignant small renal masses. The Study was authored by eight physicians in France, including interventional radiologists and urologists from Curie Institute, Paris, Nîmes University Hospital (University of Montpellier), Nîmes, and Carémeau University Hospital, Nîmes.\n\n \n \n \n \n \n \n\n \nProSense® is approved for the treatment of benign and malignant kidney tumors in the U.S., Europe, and numerous other countries.\nThe objective of this retrospective Study was to address the challenges of managing small renal masses, including recurrence rates, by exploring the safety and efficiency of single-probe percutaneous cryoablation as a potential solution. The causes of partial tumor response and persistent tumor residue after a T1a renal cryoablation procedure were assessed. A total of 25 patients underwent cryoablation for 26 T1a renal tumors with a median tumor size of 25.3 mm (20 to 30.7 mm) and a median RENAL nephrometry score, indicating tumor complexity, of 7 (5 to 9).\nMain findings of the Study:...